Rheumatoid arthritis (RA) is a chronic inflammatory joint disease, which affects -1% of adults in the developed world. Although the aetiology is poorly understood, it is clear that the proinflammatory cytokine tumour necrosis factor (TNF) plays a pivotal role in regulating the persistent inflammation characteristic of this disease. This is exemplified by the success of antiTNF therapy in many patients with RA. However, treatment with these agents is limited by expensive annual costs while a substantial, yet unpredictable, proportion of patients receive no clinical benefit.
| Identifer | oai:union.ndltd.org:bl.uk/oai:ethos.bl.uk:492877 |
| Date | January 2007 |
| Creators | Potter, Catherine |
| Publisher | University of Manchester |
| Source Sets | Ethos UK |
| Detected Language | English |
| Type | Electronic Thesis or Dissertation |
Page generated in 0.0014 seconds